Ikarian Capital, LLC Apellis Pharmaceuticals, Inc. Put Options Transaction History

Ikarian Capital, LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $5.77 Million - $8.23 Million	200,000 New	200,000 $5.77 Million
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $5.54 Million - $7.25 Million	100,000 New	100,000 $5.88 Million
Q3 2023 Nov 14, 2023	SELL	$23.65 - $89.22 $3.14 Million - $11.8 Million	-132,588 Reduced 99.69%	412 $15,000
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $10.2 Million - $12.4 Million	133,000 New	133,000 $12.1 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $1.43 Million - $3.17 Million	45,400 Added 15.13%	345,400 $11.4 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $535,790 - $850,190	13,100 Added 4.57%	300,000 $19 Million
Q4 2019 Jan 31, 2020	BUY	$22.1 - $30.8 $6.34 Million - $8.84 Million	286,900 New	286,900 $8.79 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.